
Hematology-OncologyCAR T-cell therapyDiffuse large B-cell lymphoma
Ultralow-Dose IL-10–Expressing CAR T Cells Show Promising Activity in Relapsed/Refractory DLBCL
By MedXY|Jul 25, 2026
A phase 1 trial of ultralow-dose IL-10–expressing CD19 CAR T cells in 13 patients with R/R DLBCL reported a 92.3% objective response rate with manageable safety.
